Roche's Hivid
Executive Summary
NDA filing completed Oct. 31. Hoffmann-La Roche began a rolling NDA for Hivid (ddC or zalcitabine) during the summer. The company is seeking two indications: treatment of HIV-infected individuals who have failed AZT therapy or developed an intolerance; and a first-line indication for the use of HIVID and AZT in combination. There are currently 8,000 people receiving ddC in ongoing clinical trials and in an expanded access program, begun in June 1990. . . .
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth